Daily Cardiology Research Analysis
Three cardiology studies stand out today: a biomarker sub-study from ARISTOTLE shows that shorter pre-treatment fibrin clot lysis time independently predicts bleeding on oral anticoagulants, a prospective multicenter registry demonstrates that early lung ultrasound dynamics stratify 30-day mortality in cardiogenic shock beyond SCAI staging, and a meta-analysis in Japanese AF patients suggests off-label DOAC underdosing maintains thromboembolic protection with less bleeding but higher all-cause m
Summary
Three cardiology studies stand out today: a biomarker sub-study from ARISTOTLE shows that shorter pre-treatment fibrin clot lysis time independently predicts bleeding on oral anticoagulants, a prospective multicenter registry demonstrates that early lung ultrasound dynamics stratify 30-day mortality in cardiogenic shock beyond SCAI staging, and a meta-analysis in Japanese AF patients suggests off-label DOAC underdosing maintains thromboembolic protection with less bleeding but higher all-cause mortality.
Research Themes
- Bleeding risk stratification in anticoagulated atrial fibrillation using clot lysis metrics
- Point-of-care lung ultrasound for prognosis in cardiogenic shock
- Ethnicity-specific outcomes with off-label DOAC underdosing in atrial fibrillation
Selected Articles
1. Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry-based analysis.
In a multicenter prospective registry of cardiogenic shock, 69% had extensive B-lines on admission lung ultrasound. Having ≥50% B-lines at 24 hours independently predicted higher 30-day mortality, while reduction in B-lines over 24 hours correlated with improved survival. LUS-based monitoring added prognostic value beyond SCAI classification, especially when cardiac arrest cases were excluded.
Impact: Provides actionable, bedside prognostication using lung ultrasound dynamics during the first 24 hours of cardiogenic shock, a high-risk cohort where early risk stratification is critical.
Clinical Implications: Incorporate repeat lung ultrasound within 24 hours of admission for cardiogenic shock to track B-lines; persistent high burden suggests escalated monitoring and decongestive strategies, whereas early reduction indicates favorable trajectory.
Key Findings
- Among 185 cardiogenic shock patients, 69.2% had ≥50% B-lines at admission lung ultrasound.
- B-lines ≥50% at 24 hours were independently associated with higher 30-day mortality (adjusted HR 2.23).
- Reduction in B-lines from baseline to 24 hours was associated with lower 30-day mortality (adjusted HR 0.815).
- Prognostic performance improved when excluding cardiac arrest presentations and added value beyond SCAI classification.
Methodological Strengths
- Multicenter prospective registry with standardized LUS at admission and 24 hours
- Multivariable modeling and sensitivity analysis excluding cardiac arrest improved robustness
Limitations
- Observational design susceptible to residual confounding
- Relatively modest sample size and short-term (30-day) outcomes; limited 4-zone LUS protocol
Future Directions: Randomized strategies integrating LUS-guided decongestion versus standard care in cardiogenic shock; external validation of LUS thresholds and protocols; integration with hemodynamics and biomarkers.
AIMS: Lung ultrasound (LUS) is a widely used technique to assess de-aeration in critically ill patients with respiratory failure. There is paucity of data on LUS in cardiogenic shock (CS). We sought to evaluate the epidemiology of lung congestion and its relation with outcome. METHODS AND RESULTS: The Altshock-2 registry is a multicentre, prospective, observational registry including all-comer CS patients. The LUS protocol included the examination of four zones using dichotomous assessment of lung congestion severity: ≤50% or >50%. LUS was performed at admission and at 24 h. Univariate and multivariate logistic regression analyses were performed. Overall, 185 patients (mean age 64.2 ± 13.5 years; 25.9% female) had a LUS at admission. A total of 128 patients (69.2%) had ≥50% of the investigated lung field with B-lines. At univariate Cox regression analysis, B-lines ≥50% at 24 h were significantly associated with increased 30-day mortality (hazard ratio [HR] 4.705; 95% confidence interval [CI] 2.329-9.508) and the reduction of B-lines during 24 h was associated with lower 30-day mortality (HR 0.739; 95% CI 0.571-0.956; p = 0.021). Results were confirmed at multivariate analysis after adjustment for significant covariates: B-lines ≥50% at 24 h (HR 2.23; 95% CI 1.042-8.654; p = 0.041) and the reduction in B-lines from baseline to 24 h (HR 0.815; 95% CI 0.415-1.132; p = 0.039). The sensitivity analysis, excluding patients with cardiac arrest, led to significantly increased accuracy in outcome prediction. CONCLUSION: Assessment and monitoring of lung congestion with LUS over the first 24 h in patients with CS allow to further stratify clinical outcomes with higher accuracy when added to SCAI classification, especially when excluding patients with cardiac arrest at CS presentation.
2. Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial.
In 1,841 anticoagulation-naïve ARISTOTLE participants, shorter pre-treatment fibrin clot lysis time predicted higher rates of major and clinically relevant non-major bleeding during therapy, with a graded risk across quartiles. The association was independent of allocation to apixaban versus warfarin and was not linked to cardiovascular ischemic events.
Impact: Introduces a mechanistically plausible biomarker to stratify bleeding risk in AF before initiating anticoagulation, potentially informing personalized therapy.
Clinical Implications: Consider fibrin clot lysis time as a pre-treatment biomarker to identify AF patients at elevated bleeding risk irrespective of anticoagulant choice; may guide intensity of monitoring, gastroprotection, and modifiable bleeding risk optimization.
Key Findings
- Shorter pre-treatment fibrin clot lysis time was associated with higher major and clinically relevant non-major bleeding (Q1 vs Q4 adjusted HR 2.61).
- A graded increase in bleeding risk across lysis time quartiles (Q2 and Q3 also elevated vs Q4).
- No interaction by treatment allocation (apixaban versus warfarin), and no association with composite of CV death, stroke, systemic embolism, or MI.
Methodological Strengths
- Biomarker measured prior to randomization in an RCT population with standardized turbidimetry
- Multivariable adjustment and quartile-based gradient analysis; treatment interaction tested
Limitations
- Observational biomarker analysis within a trial; potential selection of participants with available samples
- Follow-up duration for the sub-study not explicitly detailed; external validation needed
Future Directions: Prospective validation of fibrin clot lysis time cutoffs, integration into bleeding risk scores, and testing biomarker-guided anticoagulation strategies.
BACKGROUND AND AIMS: Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndromes. This study explored relationships between fibrin clot lysis time at randomization and clinical outcomes in patients with AF enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE) trial. METHODS: Plasma samples were obtained from anticoagulation-naïve participants, before initiation of study medication (n = 1841). Fibrin clot turbidimetry was performed, and lysis time determined. Associations between lysis time and characteristics, biomarkers, and on-treatment bleeding and cardiovascular events were assessed by lysis time quartile (Q1-4, shortest to longest). RESULTS: A shorter lysis time was associated with being older, male, permanent AF, lower body mass index, estimated glomerular filtration rate and C-reactive protein, and higher N-terminal pro-B-type natriuretic peptide. Major and clinically relevant non-major bleeding was significantly more frequent in lysis time Q1 vs. Q4 [6.3%/yr vs. 2.1%/yr; HR, 2.99 (95% CI, 1.75-5.12); P = .001], including after multifactorial adjustment [HR, 2.61 (1.45-4.69); P = .016]. Those in Q2 and Q3 had intermediate bleeding risk vs. Q4 [HR, 2.21 (1.27-3.87); 2.08 (1.18-3.66) respectively], suggesting a graduated effect. Treatment allocation to apixaban vs. warfarin did not affect the relationship between lysis time and bleeding (interaction-P = .80). There was no significant association between lysis time and a composite of cardiovascular death, stroke, systemic embolism or myocardial infarction. CONCLUSIONS: Shorter pre-treatment fibrin clot lysis time independently predicted higher bleeding risk in patients receiving oral anticoagulation for AF.
3. Clinical outcomes of off-label DOAC underdosing in Japanese patients with atrial fibrillation: a systematic review and meta-analysis.
Across 13 Japanese AF studies (n=37,633), off-label DOAC underdosing yielded similar rates of stroke/systemic embolism and ischemic stroke versus standard dosing, with reduced major bleeding in sensitivity analyses but higher all-cause mortality. These results highlight potential ethnic-specific dosing considerations and the need to interrogate drivers of excess mortality.
Impact: Provides the largest synthesis to date on off-label DOAC underdosing in Japanese AF, challenging one-size-fits-all dosing by showing trade-offs between bleeding and mortality.
Clinical Implications: In Japanese AF patients, off-label DOAC underdosing may maintain thromboembolic protection while reducing bleeding, but clinicians must weigh an associated increase in mortality; careful patient selection, dose justification, and close follow-up are essential.
Key Findings
- Thromboembolic outcomes (stroke/systemic embolism and ischemic stroke) were similar between underdose and standard dose groups (HR 1.03 and 1.05, respectively).
- Major bleeding was reduced with underdosing in sensitivity analyses (HR 0.77), suggesting a bleeding benefit.
- All-cause mortality was consistently higher with underdosing (HR 1.47) across primary and sensitivity analyses.
Methodological Strengths
- Large meta-analysis (13 studies; 37,633 patients) with random-effects pooling
- Sensitivity analyses restricting to studies with confounder control increased robustness
Limitations
- Observational data prone to residual confounding and heterogeneous underdosing definitions
- Lack of patient-level data to elucidate mortality signal and dosing rationale
Future Directions: Prospective, ethnicity-informed dosing studies, patient-level meta-analyses to dissect mortality drivers, and randomized trials of tailored dosing strategies.
Japanese patients with atrial fibrillation (AF) often receive underdosed direct oral anticoagulants (DOACs), deviating from standard guidelines. The impact of underdosing compared to standard dosing on thromboembolic and bleeding risks in this population remains unclear. This meta-analysis included 13 studies with 37,633 Japanese AF patients comparing underdose and standard dose groups. Efficacy outcomes included stroke or systemic embolism and ischemic stroke. Safety outcomes were major bleeding, intracranial hemorrhage, gastrointestinal bleeding, all bleeding, and all-cause mortality. Hazard ratios and 95% confidence intervals were pooled using a random-effects model. Sensitivity analyses evaluated robustness by including studies with confounder controls. Underdosing showed similar risks of stroke or systemic embolism (HR 1.03, 95% CI 0.87-1.22) and ischemic stroke (HR 1.05, 95% CI 0.85-1.31) compared to standard dosing. Major bleeding (HR 0.86; 95% CI 0.72-1.04) and all bleeding (HR 0.80; 95% CI 0.63-1.03) showed a non-significant reduction with underdosing. Sensitivity analyses confirmed a significant reduction in major bleeding risk with underdosing (HR 0.77, 95% CI 0.64-0.94). All-cause mortality was significantly higher in the underdose group throughout the primary (HR 1.47, 95% CI 1.13-1.90) and sensitivity analyses. In conclusion, Japanese patients receiving an underdose of DOACs had thromboembolic event rates comparable to those seen with standard dosing, with a reduction in bleeding events confirmed by sensitivity analyses and higher mortality. These findings indicate that ethnic-specific factors may influence DOAC effects, warranting further investigation to validate these observations and inform tailored dosing recommendations for Japanese AF patients.